Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...
Pan American Silver (TSX:PAAS) shares have posted a mixed performance recently, moving up 2% in the past day but shedding 12% ...
Ewha Womans University announced on November 7 that the research team led by Distinguished Professor Changhoe Heo of the ...
CoinsPaid, a crypto payment ecosystem for businesses, has published a comprehensive report analyzing 41 European countries ...
RotoBaller on MSN
NHL DFS Lineup Picks for DraftKings: Goalies, Value Plays, Stacks, and Power Plays Picks (11/6/25)
Tonight's nine-game slate looks to be a lot of fun. The Ducks and Stars feature multiple lines of young, exciting scorers, ...
The World Gold Council says a momentum flush out and stronger US dollar contributed to a see-saw for gold from its 50th ...
Medical device makers use AI to turn EU regulatory challenges into competitive advantages via supply chain optimization.
Welcome to Inside the Suns, your weekly deep down analysis of the current Phoenix Suns team. Each week the Fantable — a round ...
“The consistent association between GP5 responses and ETD suggests the GP5’s ability to capture how well patients tolerate ...
Clinician-Identified Health Characteristics and Palliative Care Eligibility: Is Dementia Overlooked?
Conclusions: There is a potential mismatch between what clinicians identify as important in determining palliative care need and final eligibility determinations. Patients with dementia were less ...
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback